- Home
- FVRR vs REPL Comparison
FVRR vs REPL Comparison
Compare FVRR & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FVRR | REPL |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 754.2M | 781.3M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FVRR | REPL |
|---|---|---|
| Price | $15.96 | $7.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $32.60 | $12.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 02-18-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 139.40 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $427,401,000.00 | N/A |
| Revenue This Year | $12.79 | N/A |
| Revenue Next Year | $5.73 | N/A |
| P/E Ratio | $27.91 | ★ N/A |
| Revenue Growth | ★ 12.68 | N/A |
| 52 Week Low | $15.61 | $2.68 |
| 52 Week High | $35.40 | $14.80 |
Technical Indicators
Market Signals| Indicator | FVRR | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 30.32 | 40.36 |
| Support Level | $16.50 | $6.93 |
| Resistance Level | $17.32 | $7.80 |
| Average True Range (ATR) | 0.62 | 0.44 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 17.30 | 43.48 |
Price Performance
Historical ComparisonAbout FVRR Fiverr International Ltd. no par value
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Wiring and Translation, and Video and Animation among others.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.